Skip to main content

Table 1 Clinical characteristics of studied patients

From: Reduced expression of miR-146a in human bronchial epithelial cells alters neutrophil migration

Characteristic All asthmatics Eosinophilica phenotype Neutrophilicb phenotype Paucigranulocyticc phenotype Controls
n, (%) 30 (100) 11 (36.7) 7 (23.3) 12 (40.0) 11 (100)
Gender: male/female 16/14 4/7 5/2 7/5 7/4
Age (y), mean ± SD 45.6 ± 13.1 39.8 ± 9.5 48.1 ± 18.7 49.3 ± 11.3 52.2 ± 16.6
Duration of asthma (y), mean ± SD 15.0 ± 16.3 8.3 ± 8.0 13.9 ± 7.9 21.8 ± 22.7 NA
FEV1 % predicted 81.8 ± 24.0 86.6 ± 22.7 74.2 ± 32.9 81.9 ± 20.1 111.2 ± 9.6
FEV1 % reversibility 7.2 ± 7.2 6.5 ± 5.4 6.2 ± 5.7 8.4 ± 9.5 3.0 ± 3.5
Positive skin prick test with common allergens n, (%) 15 (50.0) 4 (36.4) 4 (57.1) 7 (58.3) NA
Severity of asthma, median (IQR)d 4 (1–5) 4 (2–4) 4 (2–5) 4 (1–5) NA
Inhaled glucocorticosteroids (%, average dose μg, [range]) 96.6, 969 (0–4000) 100, 940 (250–2000) 100, 929 (500–2000) 91.6, 1020
(0–4000)
0
Systemic glucocorticosteroids n, (%) 7 (23.3) 1 (9.1) 4 (57.1) 2 (16.7) 0
  1. NA not applicable/available
  2. aEosinophilic (E), > 2% of eosinophils and < 3% of neutrophils in BALF
  3. bNeutrophilic (N), < 2% eosinophils and > 3% neutrophils in BALF
  4. cPaucigranulocytic (P), < 2% of eosinophils and < 3% neutrophils in BALF
  5. dIQR, interquartile range; asthma severity stages according to GINA (Global Initiative for Asthma) classification